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to 6% between 2008–2013. It still lags behind NICE’s 2008 benchmark of 12%, in addi-
tion to uptake in other Western countries. We aimed to understand why the UK has 
comparatively low pump uptake. Methods: We performed a structured PubMed 
literature review using search terms “Continuous subcutaneous insulin infusion” 
AND glycaemi* OR hypoglycaemi* OR “costs and cost analysis[MeSH]”, published 
after 01/01/2008. Captured articles were sifted; excluding irrelevant articles, or those 
not in English. Other relevant reports were captured by horizon scanning. Results: 
Our search terms captured 113 articles. Reviewing reports meeting the inclusion 
criteria revealed that since 2008, additional studies contribute evidence supporting 
CSII efficacy in improving HbA1c, glycaemic variability and incidence of hypogly-
caemia compared to MDI; in addition to being well-tolerated by patients. Recent 
cost-analyses suggest that CSII remains cost-effective, especially when increasing 
baseline HbA1c, hypoglycaemia avoidance, or pump life expectancy. Furthermore, 
there may be a low availability of specialised nurses, dieticians and other clinicians 
that NICE recommends are required to form part of a CSII-specialised multi-disci-
plinary team. ConClusions: It is surprising that given the amount of evidence 
supporting the efficacy, safety and cost-effectiveness of CSII, uptake of pumps by 
T1DM patients remains low in the UK. It is interesting that current evidence may be 
undermined by poor availability of clinical staff specialised in CSII, thus preventing 
new patients from effectively managing their condition.
PDB129
NeBiBe Varol
Varol N.1, Divino V2, Hallinan S.2, Dekoven M.2, Lee W.C.2, Reaney M.D.1
1Eli Lilly and Company, Windlesham, Surrey, UK, 2IMS Health, Alexandria, VA, USA
objeCtives: To evaluate treatment patterns of Type 2 diabetes (T2DM) patients 
initiating glucagon-like peptide-1 receptor agonists (GLP-1) in Canada. Methods: 
Adult T2DM patients initiating a GLP-1 between January 2010 and December 2011 
were identified using the IMS retail pharmacy database (LRx). Initiation was termed 
‘index date’. Eligible patients were naïve to GLP-1 class and had ≥ 180 days pre-index 
(with ≥ 1 oral anti-hyperglycemic agent used) and ≥ 360 days post-index of patient 
and data stability. Patients were followed through December 2012. Treatment pat-
terns over the variable-follow-up, and average daily dose of the index therapy 
while persistent were assessed. Outcomes were summarized overall and by GLP-1 
therapy: exenatide twice-daily (exBID) or liraglutide (LIRA). Results: 12,417 GLP-1 
initiators, 242 exBID and 12,175 LIRA, were included, with mean (SD) follow-up of 
14.9(1.5) and 20.6(4.8) months, respectively. Overall, approximately half were male 
(49.9%) with mean (SD) age of 57.2(9.9) years at index. 70.1% GLP-1 initiators were 
privately insured; 5.0% publicly covered and 21.4% were based on out-of-pocket 
payments. In the 180 day pre-index period, 33.7% of GLP-1 initiators used two 
concomitant anti-hyperglycemic agents, 27.9% used three, 19.7% used only one, 
and 8.4% used > 3. The most frequent concomitant medications in the pre-index 
were biguanides (75%), sulfonylureas (43.9%), and DPP-IV inhibitors (24.7%). At 
index, 35.9% of GLP-1 initiators used one concomitant anti-hyperglycemic agent 
in addition to the initiated GLP-1, while 44.3% used ≥ 2. The most frequent con-
comitant medication classes were biguanide (61.1%) and sulfonylurea (30.4%). 
Co-occurring cardiovascular medications (87.2% in the pre-index; 81.1% at index) 
were commonly used, as were lipid-lowering medications, specifically (72.6% in 
the pre-index; 62.9% at index). Over the variable-length follow-up, mean(SD) daily 
dose was 19.8(3.2)µg for exBID, 1.58(0.14)mg for LIRA. ConClusions: Treatment 
patterns varied among GLP-1 patients in Canada. Longer-term data would be use-
ful to further elucidate practice patterns.
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objeCtives: 1)Compare demographic and clinical characteristics and treat-
ment patterns of anti-vascular endothelial growth factor (VEGF) (bevacizumab, 
ranibizumab, pegaptanib) and laser therapies among diabetic macular edema 
(DME) patients; 2)Determine predictors of switching and anti-VEGF therapy initia-
tion. Methods: A retrospective cohort analysis was conducted with Texas Medicaid 
medical claims (1/1/08-12/31/12) for patients who were: 18- 63 years, continuously 
enrolled one year pre- and post-index, diagnosed with DME and treated with anti-
VEGF or laser. Treatment patterns included treatment frequency and switching 
between anti-VEGF and laser. Logistic regression was used to predict switching 
and initiation of anti-VEGF while controlling for demographic (age, gender, race) 
and clinical characteristics (visual impairment, Charlson Comorbidity Index (CCI), 
number of unique prescriptions). Results: DME patients (N= 2158) were 54.7±7.8 
years, 62.7% female and 58.3% Hispanic. 9.7% were visually impaired, CCI mean 
score was 6.5±3.2 and patients were on 2.6±3.2 unique prescriptions. A higher 
(p= 0.03) percentage of females were treated with laser (63.7%) compared to anti-
VEGF (57.6%). Anti-VEGF users (1.9±3.0) had fewer (p< 0.0001) prescriptions compared 
to laser (2.7±3.2). Laser was most commonly used (84.4%); however, anti-VEGF use 
increased from 12.6% in 2009 to 23.8% in 2011 (p< 0.0001). Patients received 2.2±1.4 
laser surgeries compared to 2.4±1.8 anti-VEGF injections. Switching from laser to 
anti-VEGF was 9.6%, while anti-VEGF to laser was 42.4%. Logistic regression showed 
that switchers were more likely to be Hispanic (OR= 1.442;95%CI= 1.053-1.975), male 
(OR= 1.333;95%CI= 1.043-1.703), have fewer prescriptions (OR= 0.946;95%CI= 0.907-
0.986) and less likely to have no visual impairment (OR= 0.620;95%CI= 0.434-0.885). 
Anti-VEGF initiators were likely to be Hispanic (OR= 1.402;95%CI= 1.032-1.906), have 
fewer prescriptions (OR= 0.909;95%CI= 0.871-0.950) and initiate in 2011 vs. 2009 
(OR= 2.298;95%CI= 1.722-3.065). ConClusions: Conclusions: Although anti-VEGF 
use in increasing, laser therapy is still more prevalent. Also, slightly over 40% of 
patients who initiated on anti-VEGF switched to laser after the first treatment. 
Additional research should be conducted to determine factors associated with this 
high rate of switching.
without previous injection experience were more likely to use a support program. 
For 67% of patients using any program, the corresponding medication was the first 
injectable taken. The proportion who rated their program as extremely useful (6 
or 7 on a 7-point scale) was 57% for BSS, 54% for VC, and 68% for LC. Overall, 49% 
reported using their program for 6 months or longer. Length of utilization was high-
est for LC with 31% reporting using the program for ≥ 1 yr. The program components 
most commonly used were educational materials (used by 75%), coupons (43%), 
telephonic support (31%), and medication reminders (8%). Use of educational mate-
rials was highest for LC, use of coupons was highest for VC, and use of telephonic 
support and reminders was highest for BSS. ConClusions: Although the minority 
of patients reported using these patient-support programs, those who did use them 
reported high levels of satisfaction and relatively long engagement.
PDB126
real life TreaTmeNT of DiaBeTes melliTus TyPe 2 PaTieNTs: aN 
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objeCtives: The aim of this claims-based data analysis was to describe the inpa-
tient/outpatient care of German T2DM patients and to determine which subgroups 
could be differentiated in terms of the achieved T2DM-related treatment results, 
the underlying comorbidities, and the achieved comorbidity-related treatment 
results. Methods: We included all T2DM patients insured by one large sickness 
fund in 2010/2011. We defined 12 different T2DM patient subgroups according to 
observed HbA1C, blood pressure, and Charlson Comorbidity Index (CCI). For each 
subgroup, available sociodemographic information, HbA1C, blood pressure, CCI, BMI, 
kidney status, and previous micro- and macrovascular events the patients expe-
rienced were reported. Furthermore, outpatient/inpatient as well as medication 
treatment was described. T2DM related events leading to acute hospitalisations 
were reported for all subgroups. Results: We included 394,828 T2DM-patients in 
our analysis (age 73.10 years; CCI 6.86); for 228,703 patients detailed laboratory 
data as basis for subgroup classification were available. For 4.5% of the patients, 
a HbA1C> 9% was observed. Across all patient subgroups, a total of 21,833 of the 
patients involved were affected by a T2DM-related event; the risk was 5.53% per 
patient year; 1.74% of the patients suffered from more than one event. Most frequent 
event types were hospitalisation with T2DM as primary diagnosis (2.39%), vascu-
lar interventions/stent implantations (1.92%), and ischaemic stroke (1.19%). There 
were significant differences between the observed subgroups in terms of T2DM-
related event risk; belonging to a specific subgroup is an independent predictor of 
the event risk. ConClusions: Overall, our data indicate that the typically treated 
T2DM patient has a number of comorbidities and thus treatment focused solely on 
T2DM is neither possible nor clinically meaningful. Particularly those patients who 
reached HbA1C goals, but had also achieved relevant additional treatment goals 
reached low yearly T2DM event rates whereas subgroups failing to achieve one or 
several treatment goals are facing much higher event risks.
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objeCtives: Diabetes mellitus (DM) is one of the diseases with the largest health 
care expenditures, with an estimated cost of $245 billion in 2012. We assessed US 
Food and Drug Administration (FDA) approval trends and manufacturer listed prices 
at approval of diabetes medications. Methods: Regulatory data were derived from 
the FDA website and average wholesaler price (AWP) per unit from the RedBook 
(Truven Health Analytics, Inc.). Descriptive statistical methods were used in the 
analysis. Results: There were 104 medications approved for DM as of January 1, 
2014. Among them, 53% were insulins and 47% oral antidiabetes drugs (OAD). The 
FDA designated 8 orphan indications for diabetes, but not orphan designations were 
approved to date. The number of insulin approvals was higher during the 1980’s and 
the number of OAD approvals was higher between 2000 and 2009. The rate of market 
discontinuation was 75.0% for insulins and 18.4% for OAD. There were a total of 23 
OADs with generic market competition. The mean time from new drug application 
approval to abbreviated new drug application approval was 15.4 years. Mean AWP 
unit prices were $1.25 for insulins and $0.30 for OADs in the 1980’s, and increased 
to $6.45 and $12.73, respectively in the 2000’s. From the 1980s to the 2000s, OAD 
manufacturer prices at approval increased by 42 times and insulin prices increased 
by 5 times. In comparison, the consumer price index increased 2.8 times during the 
same period. ConClusions: OAD products represented the largest percentage of 
new products approved for diabetes after 2000. In contrast, the number of insulin 
approvals decreased during the same period. There were not orphan approvals 
indicating the high prevalence of DM in the US. Manufacturer listed prices increased 
at higher pace than the inflation during the study period.
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objeCtives: NICE technology appraisal TA151 (Continuous subcutaneous insulin 
infusion [CSII] for the treatment of diabetes mellitus) was issued in July 2008, replac-
ing TA57 from February 2003 and recommending uptake of CSII pumps in (1) adults 
with type 1 diabetes mellitus (T1DM) who fail to reduce HbA1c < 8.5%, or disabling 
hypoglycaemia using multiple daily injections (MDI), (2) and children without requir-
ing previous MDI-failure. CSII uptake in the UK rose to 4% between 2003–2008 and 
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diabetes patients increased substantially in the past two decades. Future studies 
may consider the impact of these increases on adherence and long-term outcomes.
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exPeNDiTures
Bonakdar Tehrani A.
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objeCtives: To determine the extent to which Medicare Part D affect diabetes drug 
use and expenditures among different racial groups in the United States. Methods: 
The Medical Expenditure Panel Survey data files from 2001 to 2010 were used to 
examine changes in diabetes drug use and out-of-pocket expenditures after Part D 
implementation. I employ Difference-in-Difference (DD) methodology to compare 
racial differences in diabetes drug use and expenditures before and after 2006 for 
diabetic seniors who are covered by Part D. In other words, I compare people 65 years 
of age and older before and after Medicare Part D implementation to find the extent 
to which average diabetes drug use and expenditures have changed. Results: The 
results demonstrate that after Part D implementation diabetes drug expenditures 
significantly decreased for all senior participants on average by $199, and aver-
age diabetes drugs filled during the year increased by 0.2 but was not significant. 
Although the results show that overall diabetes drug expenditures significantly 
decreased for minorities by $159, DD estimates show that Part D increases diabetes 
drug expenditures and decreases average diabetes drug use among minorities 65 
years of age and older compared to whites by $42. ConClusions: The findings 
demonstrate that Medicare Part D significantly reduces out-of-pocket expenditures 
and increases diabetes drug use, however, African-Americans and Hispanics do not 
benefit from this reduction. In other words, Part D did not reduce racial disparities 
in diabetes drug expenditures. Additionally, Part D did not have any significant 
effect on diabetes drug use.
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DiaBeTes melliTus (T2Dm) iNiTiaTiNg caNaglifloziN from a uNiTeD 
sTaTes maNageD care samPle
Martin S.1, Henk H.2, Chow W.1
1Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2OptumInsight, Eden Prairie, MN, USA
objeCtives: Canagliflozin (CANA) is the first sodium glucose co-transporter 2 
inhibitor to be approved to treat adults with T2DM in the US. This study describes 
the early prescription pattern of patients receiving CANA in routine clinical practice. 
Clinical and demographic characteristics as well as treatment history are sum-
marized. Methods: This retrospective cohort study used data from a large US 
health plan for commercial and Medicare Advantage enrollees with T2DM filling a 
prescription for CANA between market entry on April 1 and June 30, 2013. Analysis 
included demographics, first observed dosage, prescribing specialty, antihypergly-
cemic agents (AHAs) preceding a CANA prescription, and A1C level proximal to 
initiation, where available. The diabetes complications severity index (DCSI) was 
used to capture baseline health status. Results: In this sample of patients receiv-
ing CANA (n= 1088), 44% were female, geographically skewing toward the South 
(62%). The average age was 56 years. Approximately 48%, 30%, 5% of CANA pre-
scriptions could be attributed to primary care physicians, endocrinologists, and 
other specialties, respectively, with the remainder unknown. The most common 
CANA dose was 100mg (71%). The mean (SD) number of other T2DM drug classes 
at baseline was 1.66(1.10) with oral AHA (41%) and GLP-1 (17%) being the most 
common pre-treatment monotherapies and oral AHA or GLP-1 plus insulin (31%) 
the most common pre-treatment dual therapy. For patients with available lab data 
(N= 350), 32% had baseline A1C > 9%, 38% had 7.5 to ≤ 9%, 20% had 6.5 to < 7.5%, 
and 10% had < 6.5%. The mean (SD) DCSI was 0.75(1.11); 56% had a zero DCSI value 
at baseline. ConClusions: This study characterizes patients treated in routine 
clinical practice immediately after CANA became available in the US. This early 
prescription pattern indicates CANA was prescribed by primary care physicians 
and endocrinologists across a range of A1C levels and following a variety of AHAs.
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objeCtives: To compare medication use and treatment patterns of glucagon-like 
peptide-1 receptor agonists (GLP-1RAs) among type 2 diabetes mellitus (T2DM) 
patients newly initiating exenatide once weekly (exenatide QW), exenatide twice 
daily (exenatide), or liraglutide. Methods: This administrative claims-based retro-
spective cohort study included patients if they had T2DM, were GLP-1RA-naïve, initi-
ated a GLP-1RA between 2/1/2012-1/31/2013 (initiation date= index), were aged ≥ 18 
years, and had continuous enrollment for 12 months before (baseline) to 6 months 
after index (follow-up). Outcomes included index GLP-1RA adherence (proportion 
of follow-up days covered, dichotomized at ≥ 90% vs. < 90%) and non-persistence 
(switch to non-index GLP-1RA or gap ≥ 60 days in index GLP-1RA during follow-
up). Multivariable regressions (logistic for adherence, Cox proportional hazards for 
persistence) compared outcomes among index GLP-1RAs, adjusting for potential 
confounders. Pre-specified sensitivity analyses were performed stratifying by lira-
glutide 1.2mg and liraglutide 1.8mg and among patients with ≥ 60 days’ supply 
of their index GLP-1RA within ≤ 67 days after index (initial adherers). Results: 
Samples included 4,041 exenatide QW, 4,586 exenatide, and 14,211 liraglutide 
patients. Compared with other GLP-1RAs, exenatide QW had significantly higher 
multivariable-adjusted odd ratios of index GLP-1RA adherence in all analyses (rang-
ing from 0.299 [p< 0.001] for exenatide vs. exenatide QW among initial adherers 
to 0.693 [p< 0.001] for liraglutide 1.2mg vs. exenatide QW among initial adherers).
The multivariable-adjusted hazard ratios of index GLP-1RA non-persistence var-
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objeCtives: To compare units per day per claim (units) and costs per day per claim 
(costs) of comparable insulin products by Eli Lilly and Company (LLY) and Novo 
Nordisk (NN), adjusting for baseline patient differences, in state Medicaid claims 
data. Methods: Claims for comparable LLY or NN insulin for patients with con-
tinuous coverage for ≥ 6 months before their first observed insulin claim (base-
line) were identified from Missouri (MO: 1/1/2011-3/31/2012) and New Jersey (NJ: 
1/1/2011-3/31/2013) de-identified Medicaid claims data. Units were calculated by 
multiplying total quantity per claim (in mL) by strength (1 mL= 100 units) and divid-
ing by total days supplied. Costs were calculated (for patients aged < 65 years only, 
because drug costs for those aged ≥ 65 years are often covered by Medicare rather 
than Medicaid) by dividing the cost of a claim to insurers by total days supplied. 
Regression-adjusted units and costs were estimated using generalized estimating 
equation models, accounting for baseline demographics, select comorbidities, and 
antidiabetic medication use. Results: Claims for 23,325 MO and 9,749 NJ Medicaid 
patients were analyzed. Compared with NN insulin users, LLY insulin users were 
significantly younger, had lower rates of comorbidities, and higher rate of baseline 
insulin use. The regression-adjusted units for all comparable LLY and NN insulins 
were similar, with the exception of significantly lower units for insulin lispro (MO 
only: 67.6 vs. 73.2, P= 0.0009) and LLY human insulin regular vials (MO: 65.4 vs. 
78.3, P< 0.0001; NJ: 45.3 vs. 50.3, P= 0.0365). The regression-adjusted overall cost was 
significantly lower for comparable LLY vs. NN insulin (MO: $5.7 vs. $6.1, P= 0.0046; 
NJ: $4.6 vs. $5.5, P< 0.0001). ConClusions: In both MO and NJ Medicaid, the units 
of comparable LLY and NN insulins in years evaluated were similar for patients 
with similar characteristics; however, the overall cost was significantly lower for 
comparable LLY vs. NN insulin.
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objeCtives: In Qatar, over 20% of the population has diabetes. While this is consid-
erable and is associated with a high consumption of antidiabetic drugs, there does 
not seem to be any published reports discussing the utilization and expenditure 
of antidiabetics in Qatar. This project sought to assess the trends of utilization and 
expenditure of antidiabetic drugs at Hamad Medical Corporation (HMC), the major 
health provider in Qatar, over time. Methods: The study was from the HMC per-
spective, retrospectively obtaining antidiabetics utilization and expenditure data 
from HMC drug utilization database (2007-2012). Defined Daily Doses were used as 
the utilization unit. Data were organized according to drug, drug concentration, drug 
class, hospital, and year. Descriptive statistics were used to illustrate distributions of 
variables, and cross-tabulation was used to provide comparison of frequency data, 
used to generate data tables and charts as appropriate. Results: The utilization 
and expenditure of antidiabetic drugs increased over time. The increase in utiliza-
tion seems to have been consistent with the increase in population. The expenditure 
trend however, is considerably higher. Sulfonylurea and biguanide drug classes were 
utilized the most, whereas Dipeptidylpeptidase-inhibitors were associated with the 
highest expenditure. Out of eight hospitals in HMC, Hamad General was the hospital 
that utilized drugs the most. This was consistent with antidiabetics expenditures at 
the different hospitals Of combination therapies in use, rapid-acting and intermedi-
ate-acting insulin combination was increasingly the most utilized. ConClusions: 
Expenditure trends are considerably over the increasing utilization and population 
trends, possibly indicating that the cost of drugs is not a priority consideration in 
drug selection and formulary inclusion at HMC.
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objeCtives: Management of A1c (A), blood pressure (B) and cholesterol (C) levels 
is essential to reduce the risk of diabetic complications. In the past two decades, 
the results of landmark trials have led to increasingly aggressive treatment regi-
mens and thus more intensive use of glucose-lowering, anti-hypertensive and lipid-
lowering medications for patients. We examined the trends of the use and cost 
of the three types of drugs among diabetes patients in the U.S. between 1987 and 
2010. Methods: Using the 1987 National Medical Expenditure Survey (n= 22538), 
and the Medical Expenditure Panel Survey in years 1997-98 (n= 57652) and 2009-10 
(n= 44815), we estimated the utilization and expenditures of ABC-control-related 
prescription medications among self-reported diabetes patients at the 3 time points. 
Within each drug type, usage was measured by the number of medication classes 
patients received, the share of each class and the total number of prescription 
medication encounters. Cost was measured by the payments from all payers, and 
presented in 2012 dollars. Results: Between 1987 and 2010, the number of glucose-
lowering encounters per patient nearly doubled. Patients used more varied classes. 
Usage of insulins and sulfonylureas declined from 38.7% and 67% to 29.9% and 35% 
respectively; Usage of initially unavailable medication classes – metformin, thia-
zolidinediones and DPP-4 inhibitors – increased to 59.2%, 14.5% and 9.5%, respec-
tively, in 2010. The patients that received ≥ 2 classes of glucose-lowering medications 
increased from 6% to 44%. Similar trends were observed for the other two drug 
types. The annual medical spending on glucose-lowering, anti-hypertensive and 
lipid-lowering drugs increased from $131 to $1,009, $62 to $647 and $146 to $449, 
respectively. ConClusions: Usage and cost of medications for ABC control among 
